DDReg pharma

Quailty Driven by Passion

Submit Query

Blogs

Home » Blogs » Page 13

Strengthening Safety Compliance in Somalia

All Category, Blogs, Pharmacovigilance /

The National Medicine Regulatory Authority (NMRA) of the Ministry of Health regulates and controls regulatory & safety related operations for pharmaceuticals in Somalia. It is responsible for facilitating the availability and accessibility of safe and effective medicines to the Somalian population. More recently, the Somalian NMRA issued their very first Somali Pharmacovigilance Guideline with the […]

Strengthening Safety Compliance in Somalia Read More »

Ensuring Viral Safety of Biotechnology Products

All Category, Blogs, Medical Writing /

Biotechnology products that are derived from cell lines are associated with a certain degree or risk of viral contamination. These risks can be attributed to source cell line contaminations or exogenous introduction of adventitious virus; indeed these risks need to be reduced as contamination can have major consequences. Virus testing programs have supported in assuring

Ensuring Viral Safety of Biotechnology Products Read More »

Regulatory Roadmap for Access to MedTech

All Category, Blogs, Medical Device /

In an era driven by technological advancements, particularly in healthcare, the need to implement a robust regulatory framework is more than ever to ensure compliance and patient safety. Indeed technological disruptors such as implantable medical devices, artificial intelligence, software, and diagnostics play a crucial role in healthcare whether they facilitate early detection or prevent complex

Regulatory Roadmap for Access to MedTech Read More »

Fostering Medical Innovation with Expedited Review Processes

All Category, Blogs /

2023 marked a significant year in the pharmaceutical industry as the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved an impressive 55 novel drugs. These approvals, including new molecular entities (NMEs) and new therapeutic biologics, underscore the FDA’s commitment to advancing patient care with innovative therapies. Over

Fostering Medical Innovation with Expedited Review Processes Read More »

Easing Requirements for Minimal Risk Clinical Trials

All Category, Blogs /

Expediting clinical trials that post minimal risk is important to advance healthcare & drug development. In particular, easing the requirements for informed consent regarding trial participants- for minimal risk clinical trials- can help expedite the entire clinical development process and ultimately accelerate the overall regulatory approval process. Earlier the US FDA’s regulations allowed for exceptions

Easing Requirements for Minimal Risk Clinical Trials Read More »

Standardizing Real World Data for Drug and Biological Product Submissions

All Category, Blogs /

Real world data (RWD) is proving to be an important source of information for applications such as New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), biologic license applications (BLAs) and Investigational New Drug (IND) applications. With RWD being submitted as relevant “study data”, certain agencies like the US FDA, require that the format should

Standardizing Real World Data for Drug and Biological Product Submissions Read More »

Streamlining Clinical Investigations for Medical Devices

All Category, Blogs, Medical Device /

Clinical investigations for medicinal devices are critical in order to advance healthcare and patient safety. Streamlining clinical investigations help accelerate the delivery of innovative solutions to patients, which ensures timely access to devices that would help diagnose and treat diseases. Simplifying regulatory processes, enhancing stakeholder engagement, and aligning with global practices fosters more rapid approvals.

Streamlining Clinical Investigations for Medical Devices Read More »

Third Party Review Program for Medical Devices

All Category, Blogs, Medical Device /

The onset of the pandemic highlighted many obstacles pertaining to medical devices used to detect and diagnose the virus, SARS-CoV-2. Many device manufacturers emerged with their concerns and requested for “Emergency-Use Authorization” (EUA) for their in vitro diagnostic medical devices used to help detect the virus. In response to this request, the US FDA provided

Third Party Review Program for Medical Devices Read More »

SwissMedic: Strengthening Safety Signal Reporting for Veterinary Products

All Category, Blogs, Pharmacovigilance /

Efficiently detecting safety signals for veterinary products is crucial for safeguarding animal health and ensuring the well-being of both animals and humans. Rapid identification of potential risks allows for timely intervention, preventing widespread harm. Recognizing the significance of this, global authorities are actively working to fortify safety signal reporting. Establishing regulatory guidelines ensures a standardized

SwissMedic: Strengthening Safety Signal Reporting for Veterinary Products Read More »

Effective Communication for the Safe Use of Biosimilars

All Category, Blogs, Labeling /

Biosimilars and interchangeability with biologics has been a topic of discussion for regulatory authorities worldwide, including their definitions and varying requirements per regions. However, a key requirement or standard for interchangeability requires applicants to provide sufficient information to demonstrate bio similarity. This reflects in the biosimilars labelling requirements where prescription drug and biological product labels

Effective Communication for the Safe Use of Biosimilars Read More »